Caris Life Sciences, Inc. (CAI): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$22.61M
Year ended 2025-12-31
$20.76M
Trailing 12 months to 2026-06-30
$49.00M2023-12-31: $49.00M2024-12-31: $48.91M2025-12-31: $22.61M$22.61M
2023-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$22.61M-53.8%2026-03-03, From 2025-01-01
2024-12-31$48.91M-0.2%2026-03-03, From 2024-01-01
2023-12-31$49.00Mn/a2026-03-03, From 2023-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Caris Life Sciences, Inc. (CAI)2025-12-31$22.61M-53.8%
Guardant Health, Inc. (GH)2025-12-31$39.74M-6.3%
Veracyte, Inc. (VCYT)2025-12-31$21.41M-8.7%
CareDx, Inc. (CDNA)2025-12-31$15.02M+5.8%
Castle Biosciences Inc (CSTL)2025-12-31$40.77M+154.9%
RadNet, Inc. (RDNT)2025-12-31$136.10M+8.6%
Fulgent Genetics, Inc. (FLGT)2025-12-31$24.12M-3.2%
BillionToOne, Inc. (BLLN)2025-12-31$6.90M-1.4%
Natera, Inc. (NTRA)2025-12-31$41.76M+34.9%

Compare CAI, GH, VCYT, CDNA side by side · Screen every company in Services-Medical Laboratories ↗